FDA approves new version of plasma therapy from Talecris
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
RESEARCH TRIANGLE PARK, N.C. – The U.S. Food and Drug Administration has approved a new blood plasma-based therapeutic from Talecris Biotherapeutics (Nasdaq: TLCR) that targets a condition known as Alpha-1.
Talecris developed a new version of a 20-year-old product called Prolastin that helps victims of the alpha 1-antitrypsin deficiency prevent the onset of emphysema. Alpha-1 is a genetic disorder.
Called Prolastin-C, the new therapy bolsters protein levels with half the volume and in half the time than required by the earlier version.
"The introduction of Prolastin revolutionized care for thousands of individuals with Alpha-1," said John Walsh, chief executive officer of the Alpha-1 Foundation. "We welcome Prolastin-C as an example of the ongoing commitment Talecris has made to the Alpha-1 community."
Talecris was able to improve Prolastin through manufacturing techniques focused on a virus exclusion technology and an additional purification step. It is based on blood plasma.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
The Skinny
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO